In the tumor model of mice with heterozygous mutations in TSC2 (Tsc2+/- ) there was no reduction in tumor size after metformin treatment compared with those treated with rapamycin, suggesting limited therapeutic benefits of metformin in treating hamartomas (Auricchio et al., 2012). Here, TSC2 is linked to neoplasm.